STOCK TITAN
  1. Home
  2. News
  3. CNSP

CNS Pharmaceuticals, Inc. - CNSP STOCK NEWS

Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) is a Houston-based clinical-stage biopharmaceutical company established in 2017. The company is dedicated to developing novel anticancer drug candidates aimed at treating primary and metastatic cancers of the brain and central nervous system (CNS). Their lead drug candidate, Berubicin, is a pioneering anthracycline that distinguishes itself by its ability to cross the blood-brain barrier, offering new hope for patients suffering from glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer.

Berubicin has shown promise in initial trials, with the Phase I clinical trial completing successfully. As of now, Berubicin is being evaluated in a potentially pivotal study. The preliminary safety data was presented at the Society of NeuroOncology (SNO) 28th Annual Meeting, highlighting its comparability in patient demographics and safety with the control arm of the study. Encouragingly, the independent Data Safety Monitoring Board (DSMB) recommended the continuation of the trial without modification after a pre-planned interim futility analysis, signifying Berubicin’s acceptable efficacy and safety profile.

The company has also secured several important collaborations and licensing agreements, including partnerships with Houston Pharmaceuticals, Inc., the University of Texas M.D. Anderson Cancer Center, and WPD Pharmaceuticals Inc. These agreements bolster the development pipeline and provide access to cutting-edge research and development facilities.

Financially, CNS Pharmaceuticals is proactive in securing necessary funding for their research endeavors. Recent public offerings and strategic financial management have ensured operational continuity and support for their ongoing clinical trials. Despite the inherent risks and uncertainties of drug development, CNS Pharmaceuticals remains steadfast in their mission to develop effective cancer therapies.

Beyond Berubicin, CNS Pharmaceuticals continues to explore additional drug candidates and therapies to address various CNS oncology indications. The company's commitment to innovation and patient care positions it as a potential leader in the fight against some of the most challenging cancer types.

For more information, please visit www.CNSPharma.com and connect with the company on Twitter, Facebook, and LinkedIn.

News

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Rhea-AI Summary
CNS Pharmaceuticals, Inc. announces the completion of planned enrollment in its global potentially pivotal study evaluating Berubicin for the treatment of GBM, an aggressive and incurable form of brain cancer. The study has enrolled 247 patients across 46 clinical trial sites in the U.S., Italy, France, Spain, and Switzerland. The interim analysis of efficacy and safety data in the study was successfully completed, with a positive recommendation from the independent Data Safety Monitoring Board (DSMB) to continue the trial without modification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
none
-
News

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

Rhea-AI Summary
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) receives a positive recommendation from the independent DSMB to continue the clinical trial of Berubicin without modification. The trial is expected to be complete in early Q1 2024. The DSMB's recommendation follows a pre-specified futility analysis of unblinded efficacy and safety data, supporting the acceptable efficacy and safety profile of Berubicin. The potentially pivotal study of Berubicin is a multicenter, open-label, randomized controlled study in adult patients with recurrent GBM (WHO Grade IV) after failure of standard first-line therapy and compared to Lomustine. The CEO of CNS Pharma, John Climaco, expressed optimism about the study's progress and the potential for Berubicin to address the unmet clinical need of GBM patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.12%
Tags
none
-
News

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

Rhea-AI Summary
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is developing innovative therapies for central nervous system disorders, particularly aggressive brain cancers. Their leading treatment candidate, Berubicin, is showing promising results in an ongoing study for recurrent GBM, a highly aggressive and incurable form of brain cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
none
News

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

Rhea-AI Summary
CNS Pharmaceuticals, Inc. (CNSP) presented updated safety data on Berubicin, its novel anthracycline being evaluated for the treatment of Glioblastoma Multiforme (GBM) at the Society of NeuroOncology (SNO) 28th Annual Meeting. The topline result from the preplanned interim futility analysis is expected in December 2023. The data showed the comparability of patient demographics and safety data for each therapeutic modality in treating recurrent GBM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.66%
Tags
none
-
News

CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate

Rhea-AI Summary
CNS Pharmaceuticals Set To Release Data On GBM Drug Candidate. CNS Pharmaceuticals (NASDAQ:CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. One of their leading treatment candidates is Berubicin, a chemotherapy drug that interferes with the DNA of cancer cells to inhibit their growth and potentially shrink tumors. Berubicin is an anthracycline, a clinically trusted class of drugs in use for 60 years against dozens of common cancers. The company has received FDA Orphan Drug Designation and Fast Track Designation, and is conducting a potentially pivotal clinical trial designed to evaluate the safety and effectiveness of Berubicin. Results from an earlier trial showed a clinical response in 44% of patients. The company announced that 229 out of 243 expected patients had already been enrolled in their ongoing study evaluating the effectiveness of Berubicin for recurrent GBM, a highly aggressive and incurable form of brain cancer. The company is confident that it will share the results from this interim analysis with the public before the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.38%
Tags
none
-
News

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

Rhea-AI Summary
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) reported enrollment numbers rising to 239 in the ongoing potentially pivotal study of Berubicin for the treatment of GBM. The company expects full enrollment in December 2023. Topline data from a preplanned interim analysis from the ongoing Berubicin potentially pivotal study is also expected in December 2023. The company raised $2.6 million subsequent to the quarter-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.97%
Tags
earnings
News

CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference

Rhea-AI Summary
CNS Pharmaceuticals' CEO, John Climaco, will participate in the Virtual Investor Ask the CEO Conference on October 24th. The conference allows investors to ask questions directly to management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.24%
Tags
conferences
-
News

CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date

Rhea-AI Summary
CNS Pharmaceuticals achieves enrollment of 229 patients in pivotal study for brain cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.28%
Tags
none
-
News

CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)

Rhea-AI Summary
CNS Pharmaceuticals enrolls 200 patients in pivotal study for Berubicin treatment of recurrent GBM, on track to announce interim data results by end of 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
none
News

CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary
CNS Pharmaceuticals to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.51%
Tags
conferences

FAQ

What is the current stock price of CNS Pharmaceuticals (CNSP)?

The current stock price of CNS Pharmaceuticals (CNSP) is $0.109 as of December 24, 2024.

What is the market cap of CNS Pharmaceuticals (CNSP)?

The market cap of CNS Pharmaceuticals (CNSP) is approximately 6.3M.

What is CNS Pharmaceuticals' primary focus?

CNS Pharmaceuticals specializes in developing novel treatments for primary and metastatic cancers in the brain and central nervous system.

What is Berubicin?

Berubicin is CNS Pharmaceuticals' lead drug candidate, a novel anthracycline designed to treat glioblastoma multiforme (GBM) and other serious brain cancers by crossing the blood-brain barrier.

What makes Berubicin different from other cancer treatments?

Berubicin is the first anthracycline to appear to cross the blood-brain barrier, potentially making it more effective against brain cancers compared to traditional chemotherapy drugs.

What stage is Berubicin currently in?

Berubicin is currently undergoing a potentially pivotal study, with promising interim safety results and a recommendation to continue the trial without modification.

What recent achievements has CNS Pharmaceuticals reported?

CNS Pharmaceuticals recently completed planned enrollment for its Berubicin trial, received DSMB's recommendation to continue the study without modification, and announced positive interim safety data.

Who are CNS Pharmaceuticals' key partners?

CNS Pharmaceuticals has partnerships with Houston Pharmaceuticals, Inc., the University of Texas M.D. Anderson Cancer Center, and WPD Pharmaceuticals Inc.

What financial steps has CNS Pharmaceuticals taken recently?

CNS Pharmaceuticals has conducted public offerings to secure funding for its ongoing clinical trials and research and development efforts.

What designations has the FDA granted to Berubicin?

The FDA has granted Berubicin Fast Track Designation, enabling more frequent interactions for expediting development, and Orphan Drug Designation, which may provide seven years of marketing exclusivity upon approval.

What is the primary endpoint of the Berubicin study?

The primary endpoint is Overall Survival (OS), which the FDA recognizes as a basis for oncology drug approval when a statistically significant improvement is shown.

How does CNS Pharmaceuticals ensure the accuracy and safety of its trials?

CNS Pharmaceuticals relies on an independent Data Safety Monitoring Board (DSMB) to review interim data and ensure the safety and efficacy of its clinical trials.

Stock CNSP logo
CNS Pharmaceuticals, Inc.

Nasdaq:CNSP

CNSP Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

CNSP Stock Data

6.27M
56.89M
1.04%
0.79%
2.79%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HOUSTON